It's not over because management is unethical and manipulators. Like Galena they will make up BS to bring in naive investors so they can sell more shares and enrich THEMSELVES. Not you, not me, not the patients, only themselves. If they had a great drug, a big pharma would have swooped in and bought them out which enriches everyone at a 2x premium. Because this didn't happen since their drug is ineffective, the only way for management to enrich themselves is to continue selling BS in the form of shares. It is the dark world of biotech...
Which occurs first, cardiotoxity which is 9-11% in patients or withdrawal from extended dosing that would benefit? You need to consider this and not believe in management's propaganda.
GALE was his brain child as well. Both are frauds...shareholders and lawyers will be out for blood.
No...you guys just don't get it. Aldoxo is for second-line, and it has just failed PFS because it is exactly like doxo regardless of increasing dose. Look at literature for doxo as second-line for STS...it will not increase OS. Management will need to increase cash and reverse split to keep ticker alive. Read up on "biotech zombies."
Statistics don't lie. Several papers have been published on price decline and increase via friday and monday release as well PM and AM. You are naive to believe otherwise. This is a PR tactic, management can tell CROs to provide updates on Monday and Friday only which aligns timing of PR release. Get with it.
Haha, so many people starting to rationalize a phase 3 failure by talking about preclinical. Where are they going to get money to run all of these promising treatments? The money comes from diluted shareholders who management doesn't give a thought to.
With a phase 3 failure, management will need to dilute to get that program going. Why isn't anyone looking at the obvious red flag? If aldox is so promising, why don't they have a hint of a partnership??? Many have tried to best SOC for STS and many have failed. CYTR went from first line to second-line...that's proof that they're not confident.
Digging through poop trying to figure out why it's poop doesn't change the fact that it is still poop. People still died... GALE management are sleazy and I nominate them as the worst biotech company and ceo ever! I suspect CYTR will join GALE in this nomination soon enough.
Can you tell me what dox +ifos response% and pfs is? Once you do you may think twice about aldox having a positive topline.
Yes, so now we speculate:
Good - this shows management wants to draw attention to aldox when the good news comes
Bad - this shows management doesn't want to be seen when the bad news comes
LOL, did you buy before or after the 100 reverse split?
By this Friday or next Friday you will know the game is up. Will fall to less than 50c.
Hey pumper! How was ACTC/ocata...think it will reverse split here as well? I sure think so.
Increasing subject count is usually a sign that the trial is going to fail. It's a last ditched effort to improve p value. Anyone calculate the timing of the events to get a rough number for PFS months? It was very obvious for CPXX and easy to calculate. I have a hard time reconciling doxo data of min. 20% response vs. 0% response in data.